We’re excited to announce the launch of the Daily Mushroom Store.
Check out our hats, beanies, t-shirts, hoodies, and mugs, and be sure to follow us on Instagram @dailymushroom.co for a chance to win free goodies.
Ninnion Therapeutics, a private Texas-based company, hopes microdosing will help patients recover from strokes.
Ischemic strokes block blood flow to the brain, causing brain cells to die.
Microdosing in combination with occupational therapy may be able to strengthen the remaining brain cells to restore lost functions.
The company recently filed a patent application for the treatment. Since there are no approved drugs for stroke recovery, the formulation may qualify for a Breakthrough Therapy designation, which would speed up the development timeline.
Nue Life raised $23M in equity financing to support the expansion of its innovative at-home ketamine services into more than 20 new states this year.
By denying Canadians access to psilocybin, the government is infringing on patients’ rights. According to TheraPsil, the decision to use psilocybin medically should be made between doctor and patient with no requirement for government approval (just like medical cannabis).
If you believe that access to psilocybin for medical purposes is a right, please help TheraPsil prove this in court by donating to their fundraiser.
Ehave Inc. (EHVVF) and University of Melbourne are launching a series of studies to better understand a condition called hallucinogen-persisting perception disorder (HPPD). Basically, HPPD is when someone continues to experience visual hallucinations after a trip.
Researchers will conduct genetic analysis and visual processing tests to see if individuals can be genetically predisposed to HPPD.
Ehave’s goal is to find a cure for the disorder and become an “industry leader in preventing negative side effects during treatment for mental health issues.”
Filament Health (FH) granted Psyence Group (PSYG) an exclusive license to use its natural psilocybin formulation in an upcoming palliative care trial in the UK. Filament recently received a patent for its technology for extracting and standardizing natural psilocybin.
Activists in Massachusetts are pushing for decriminalization of all illicit drugs (with a focus on psychedelics) in the city of Worceter and at the state level.
Irwin Naturals (IWIN), a major supplement company established in 1994, is acquiring a chain of ketamine clinics in Florida and Mexico, becoming the “world’s first household name to enter the psychedelic mental health treatment sector.” This acquisition is part of a plan to create the world’s largest chain of psychedelic clinics.
Wesana Health (WESA) may expand the indication of its psilocybin formulation after meeting with the FDA. In addition to treating anxiety related to traumatic brain injury, it could also target depression. A $3M private placement will fund phase Ib/IIa depression study next year.
The Colorado House passed a bill to allow the prescription of MDMA if and when the federal government legalizes its use.
